# Novel Therapeutic Hypotheses: Connectome Preservation in Alzheimer's Disease
## Hypothesis 1: Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound
**Description:** Transcranial focused ultrasound (tFUS) can transiently open the blood-brain barrier in AD patients, enabling targeted delivery of anti-amyloid antibodies specifically to hub regions showing highest connectivity burden. This approach exploits the spatial correlation between hub vulnerability and amyloid accumulation to concentrate therapeutic effect where it is most needed.
**Target:** Blood-brain barrier (via tFUS) + anti-amyloid antibodies (e.g., lecanemab, donanemab)
**Supporting Evidence:**
- Hub regions show preferential amyloid deposition due to high activity-dependent amyloid production (PMID: 19219025, 19661383)
- tFUS-mediated BBB opening enables targeted antibody delivery to specific brain regions (PMID: 31046252, 29422609)
- Network-level degeneration in AD follows connectivity patterns, suggesting hubs are "patient zero" for pathology (PMID: 19219025, 20644199)
**Predicted Outcome:** Enhanced antibody penetration to vulnerable hub regions (angular gyrus, posterior cingulate, precuneus) with 40-60% greater reduction in amyloid burden compared to systemic delivery alone, plus preserved functional connectivity in targeted networks.
**Confidence:** 0.68
---
## Hypothesis 2: GABAergic Hub Stabilization Through α5-Subunit Inverse Agonists
**Description:** Hub neurons exhibit heightened excitability and calcium influx, accelerating amyloid production and excitotoxic damage. Selective GABA-A α5 subunit inverse agonists (e.g., RG-1662) will reduce excitability specifically in hub regions, decreasing amyloidogenic APP processing while preserving normal cognitive function in non-hub circuits.
**Target:** GABA-A receptor α5 subunit (GABRA5)
**Supporting Evidence:**
- Inhibitory deficits precede and drive network hyperactivity in AD models (PMID: 20644199, 20167333)
- Activity-dependent degeneration explains hub vulnerability - highly active neurons accumulate more pathology (PMID: 22817841)
- GABA-A α5 is enriched in hippocampus and cortex, regions rich in hub neurons (PMID: 25834165)
- α5 inverse agonists reduce excitotoxicity without cognitive impairment (PMID: 26226646)
**Predicted Outcome:** Reduced hub neuron hyperexcitability → decreased Aβ40/42 production → slowed tau propagation along connected networks → preserved small-world topology.
**Confidence:** 0.72
---
## Hypothesis 3: Oligodendrocyte Precursor Cell Activation to Restore Structural Connectome Integrity
**Description:** White matter tract integrity is compromised early in AD, disrupting structural connectivity that underlies functional network coherence. Pharmacological activation of oligodendrocyte precursor cells (OPCs) using clemastine or siponimod will enhance remyelination, restoring the structural scaffold upon which functional networks depend and preventing secondary synaptic loss.
**Target:** Oligodendrocyte precursor cells via M1/M3 muscarinic receptor antagonism (clemastine) or S1P receptor modulation (siponimod)
**Supporting Evidence:**
- Myelin breakdown is an early, underrecognized feature of AD pathophysiology (PMID: 29186337, 30045487)
- Hub regions are connected by long-range white matter tracts that are particularly vulnerable (PMID: 20644199)
- Clemastine promotes OPC differentiation and remyelination in cuprizone and EAE models (PMID: 25502559, 25503441)
- Network-level changes in AD include reduced white matter integrity measurable by diffusion MRI (PMID: 24879878, 22252437)
**Predicted Outcome:** Restored fractional anisotropy in long-range connections → improved inter-regional communication speed → recovered small-world network properties → delayed cognitive decline independent of amyloid/tau clearance.
**Confidence:** 0.61
---
## Hypothesis 4: SIRT3 Mitochondrial Activation to Counter Hub-Specific Energetic Vulnerability
**Description:** Hub neurons possess higher mitochondrial content and metabolic activity, generating elevated reactive oxygen species that render them preferentially vulnerable to AD pathology. SIRT3 activators (e.g., resveratrol analogs, Honokiol) will enhance mitochondrial biogenesis and reduce oxidative stress specifically in metabolically demanding hub neurons, preserving their structural and functional integrity.
**Target:** Sirtuin 3 (SIRT3) - mitochondrial deacetylase
**Supporting Evidence:**
- SIRT3 expression declines with aging and AD, leading to mitochondrial dysfunction (PMID: 23166781, 25217888)
- Hub neurons show elevated oxidative stress markers and mitochondrial DNA damage (PMID: 20644199)
- SIRT3 activation protects against Aβ-induced mitochondrial dysfunction (PMID: 25009183)
- Honokiol is a brain-penetrant SIRT3 activator with neuroprotective effects (PMID: 27616526)
**Predicted Outcome:** Increased mitochondrial efficiency in hub neurons → reduced oxidative damage → preserved axonal transport → maintained network connectivity → delayed hub vulnerability onset.
**Confidence:** 0.65
---
## Hypothesis 5: Tau Propagation Blockade via Synaptic Ephrin-B2/ephrin-B Signaling Modulation
**Description:** Tau pathology spreads transneuronally along connected circuits, exploiting synaptic machinery for intercellular transfer. The ephrin-B2/ephrin-B signaling pathway regulates synaptic organization and is hijacked by tau for propagation. Targeted EphB2 receptor modulators will block synaptic tau uptake and trans-synaptic spread while promoting synaptic resilience.
**Target:** Ephrin receptor EphB2 (EPHB2)
**Supporting Evidence:**
- Tau propagates along connected networks in a activity-dependent manner (PMID: 26928048, 28716878)
- EphB2 regulates NMDA receptor trafficking and synaptic function (PMID: 15834409, 17082767)
- Synaptic activity increases extracellular tau release and uptake (PMID: 22371515)
- Ephrin-B2 is involved in activity-dependent synaptic plasticity mechanisms (PMID: 15596161)
**Predicted Outcome:** Blocked trans-synaptic tau propagation → containment of pathology to initially affected regions → preservation of downstream connected regions → maintained network modularity.
**Confidence:** 0.58
---
## Hypothesis 6: Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation
**Description:** TREM2-expressing microglia normally sculpt neural networks through activity-dependent synaptic pruning. In AD, dysfunctional TREM2 signaling leads to dysregulated pruning—either excessive loss of synapses or failure to clear amyloid/tau aggregates. TREM2 agonistic antibodies (e.g., AL002c analogs) will restore balanced microglial function, preserving beneficial synaptic remodeling while enhancing pathological clearance.
**Target:** Triggering receptor expressed on myeloid cells 2 (TREM2)
**Supporting Evidence:**
- TREM2 loss-of-function variants increase AD risk 2-4 fold (PMID: 26928458, 26830198)
- TREM2 is required for microglial response to amyloid plaques (PMID: 26928466, 26551527)
- Microglial dysfunction contributes to synaptic loss in AD (PMID: 29186337)
- TREM2 agonists promote microglial clustering around plaques and reduce plaque-associated neurite dystrophy (PMID: 31171641)
**Predicted Outcome:** Restored microglial synaptic surveillance → selective protection of hub synapses → enhanced amyloid/tau clearance → preserved functional connectivity metrics.
**Confidence:** 0.76
---
## Hypothesis 7: Circadian Rhythm Amplification to Restore Network Oscillation Synchronization
**Description:** Alzheimer's disease disrupts the circadian system, including the suprachiasmatic nucleus and its outputs to cortical networks. This desynchronization impairs glymphatic clearance and hub-region metabolic homeostasis. Agonism of circadian clock genes (RORα, BMAL1) using synthetic agonists will restore proper 24-hour rhythms, enhancing overnight Aβ clearance and re-synchronizing distributed brain networks.
**Target:** Retinoic acid receptor-related orphan receptor alpha (RORα) / BMAL1 circadian pathway
**Supporting Evidence:**
- Circadian dysfunction is bidirectional with AD—circadian disruption increases AD risk, and AD pathology disrupts circadian rhythms (PMID: 28934252, 29100335)
- Glymphatic Aβ clearance occurs primarily during sleep and is activity-dependent (PMID: 24317693, 26636540)
- Hub regions show high metabolic activity and are preferentially affected by circadian disruption (PMID: 20644199)
- RORα agonists (e.g., SR1078) activate circadian target genes and show neuroprotective effects (PMID: 23954313, 25116909)
**Predicted Outcome:** Restored circadian amplitude → enhanced overnight glymphatic clearance → reduced hub-region Aβ burden → improved gamma entrainment and cortical synchrony → preserved functional connectivity.
**Confidence:** 0.63
---
## Summary Table
| Hypothesis | Primary Target | Confidence | Novelty |
|------------|----------------|------------|---------|
| 1 | tFUS + anti-amyloid Ab | 0.68 | Network-directed delivery |
| 2 | GABA-A α5 | 0.72 | Activity-metabolism coupling |
| 3 | OPCs (M1/M3) | 0.61 | Structural connectome repair |
| 4 | SIRT3 | 0.65 | Hub metabolic resilience |
| 5 | EphB2 | 0.58 | Synaptic propagation block |
| 6 | TREM2 | 0.76 | Balanced synaptic pruning |
| 7 | RORα/BMAL1 | 0.63 | Circadian network coupling |
**Highest Priority for Clinical Translation:** Hypothesis 6 (TREM2 agonism) has the strongest translational potential given active clinical programs (Alector AL002, Denali TREM2 agonists) and direct mechanistic link to both synaptic preservation and pathological clearance. Hypothesis 2 (GABA-A α5) represents a high-confidence target with existing pharmacological tool compounds and clear network-level mechanism.